Drug: INFLIXIMAB Injury: Hepatosplenic T-cell lymphoma Quarter: 2016Q3
Total Records: 17 Number of Pages: 1
Event ID | DRUGNAME | PT | Drug Manufacturer | Patient Age | Sex | Weight | Date (YYYYMMDD) | Country |
---|---|---|---|---|---|---|---|---|
125181152 | INFLIXIMAB | Hepatosplenic T-cell lymphoma | APOTEX | 0.00 | F | 0 | 20160718 | CA |
127363891 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 24.00 YR | M | 0 | 20160913 | US |
127363941 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 31.00 YR | M | 0 | 20160913 | COUNTRY NOT SPECIFIED |
127407411 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 22.00 YR | M | 0 | 20160914 | US |
127408491 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 52.00 YR | M | 0 | 20160914 | US |
127408571 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 0.00 | F | 0 | 20160914 | US |
127408581 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 31.00 YR | M | 0 | 20160914 | US |
127408601 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 17.00 YR | F | 0 | 20160914 | US |
127408641 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 28.00 YR | M | 0 | 20160914 | US |
127408651 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 19.00 YR | M | 0 | 20160914 | US |
127408661 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 53.00 YR | M | 0 | 20160914 | US |
127408671 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 31.00 YR | M | 0 | 20160914 | US |
127408681 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 19.00 YR | M | 0 | 20160914 | US |
127408691 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 20.00 YR | M | 0 | 20160914 | US |
127408701 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 15.00 YR | M | 0 | 20160914 | US |
127408721 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 12.00 YR | M | 0 | 20160914 | US |
127410371 | Infliximab | Hepatosplenic T-cell lymphoma | RANBAXY | 18.00 YR | M | 0 | 20160914 | US |
Total Records: 17 Number of Pages: 1